Scholarlink

<p>Treatment options for patients with gliomas remain limited, and prognosis is generally poor. While next-generation sequencing (NGS) is increasingly used to stratify glioma patients and guide therapy, its implementation in routine clinical practice remains variable. We conducted a multicenter retrospective study across seven Spanish hospitals to evaluate the clinical utility of NGS in glioma management, focusing on its impact on diagnosis and treatment selection based on the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). A total of 541 glioma patients diagnosed between 2018 and 2022 were included; 76% had glioblastomas and 24% other glioma subtypes. Among glioblastoma patients, 9% harbored ESCAT tier 1/2 alterations and 74% tier 3/4. Molecularly matched therapy was administered in 10.2% of glioblastoma cases. Objective responses were observed in 17.6% of glioblastoma and 33% of non-glioblastoma patients with ESCAT tier 1/2 alterations. Patients with tier 1/2 alterations experienced significantly longer progression-free survival compared to those with tier 3/4. These findings support genomic profiling of gliomas in research centers to expand therapeutic options in molecularly guided clinical trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月6日

查看全文
  • Oriol Mirallas,
  • Fiorella Ruiz-Pace,
  • Gabriel Velilla,
  • Diego Gómez-Puerto,
  • Teresa Gorria,
  • Jesus Yaringaño,
  • Álvaro Martínez-Monino,
  • Daniel López-Valbuena,
  • Maria Angeles Vaz,
  • Ainhoa Hernandez,
  • Elena Martínez-Saez,
  • Maria Aguado Sorolla,
  • Maria Castro-Henriques,
  • Julia Lostes Bardaji,
  • Antonio Di Muzio,
  • Oscar Gallego,
  • María Martínez-García,
  • Marta Domenech,
  • Joan Carles,
  • Carmen Balaña,
  • Estela Pineda,
  • Rodrigo Dienstmann,
  • Juan Manuel Sepúlveda,
  • Maria Vieito

摘要

Treatment options for patients with gliomas remain limited, and prognosis is generally poor. While next-generation sequencing (NGS) is increasingly used to stratify glioma patients and guide therapy, its implementation in routine clinical practice remains variable. We conducted a multicenter retrospective study across seven Spanish hospitals to evaluate the clinical utility of NGS in glioma management, focusing on its impact on diagnosis and treatment selection based on the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). A total of 541 glioma patients diagnosed between 2018 and 2022 were included; 76% had glioblastomas and 24% other glioma subtypes. Among glioblastoma patients, 9% harbored ESCAT tier 1/2 alterations and 74% tier 3/4. Molecularly matched therapy was administered in 10.2% of glioblastoma cases. Objective responses were observed in 17.6% of glioblastoma and 33% of non-glioblastoma patients with ESCAT tier 1/2 alterations. Patients with tier 1/2 alterations experienced significantly longer progression-free survival compared to those with tier 3/4. These findings support genomic profiling of gliomas in research centers to expand therapeutic options in molecularly guided clinical trials.